Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma

Epigenetics

Volumn 10, Issue 6, 2015, Pages 460-466

  Sengupta, Deepanwita ^a   Kannan, Aarthi ^a   Kern, Malan ^a   Moreno, Mauricio A ^a   Vural, Emre ^a   Stack, Brendan ^a   Suen, James Y ^a   Tackett, Alan J ^a   Gao, Ling ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

BET inhibitor; BRD4; H3K27Ac; JQ1; Merkel cell carcinoma; Super enhancer

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO [3,2F] [1,2,4] TRIAZOLO [4,3A] [1,4] DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; ACETYLATED HISTONE H3 LYSINE 27; BROMODOMAIN PROTEIN 4; MYC PROTEIN; NUCLEAR PROTEIN; UNCLASSIFIED DRUG; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; BRD4 PROTEIN, HUMAN; CHROMATIN; HISTONE DEMETHYLASE; KDM6B PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN C MYB; TRANSCRIPTION FACTOR; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; ENHANCER REGION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; MERKEL CELL TUMOR; MOUSE; NONHUMAN; ONCOGENE C MYC; PROTEIN BINDING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING; ACETYLATION; ANIMAL; APOPTOSIS; BIOSYNTHESIS; CARCINOMA, MERKEL CELL; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; METASTASIS; PROMOTER REGION; SKIN NEOPLASMS; TUMOR CELL LINE;

ACETYLATION; ANIMALS; APOPTOSIS; AZEPINES; CARCINOMA, MERKEL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN; ENHANCER ELEMENTS, GENETIC; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; MICE; NEOPLASM METASTASIS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MYB; SKIN NEOPLASMS; TRANSCRIPTION FACTORS; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84943747585     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.1080/15592294.2015.1034416     Document Type: Article

References (28)

1. Iyer JG, Storer BE, Paulson KG, Lemos B, Phillips JL, Bichakjian CK, Zeitouni N, Gershenwald JE, Sondak V, Otley CC, et al. Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma. J Am Acad Dermatol 2014; 70: 637-43; PMID: 24521828; http://dx. doi. org/10. 1016/j. jaad. 2013. 11. 031.
2. Hughes MP, Hardee ME, Cornelius LA, Hutchins LF, Becker JC, Gao L. Merkel cell carcinoma: epidemiology, target, and therapy. Curr Dermatol Rep 2014; 3: 46-53; PMID: 24587977; http://dx. doi. org/10. 1007/s13671-014-0068-z.
3. Schrama D, Peitsch WK, Zapatka M, Kneitz H, Houben R, Eib S, Haferkamp S, Moore PS, Shuda M, Thompson JF, et al. Merkel cell polyomavirus status is not associated with clinical course of Merkel cell carcinoma. J Invest Dermatol 2011; 131: 1631-8; PMID: 21562568; http://dx. doi. org/10. 1038/jid. 2011. 115.
4. Paulson KG, Lemos BD, Feng B, Jaimes N, Peñas PF, Bi X, Maher E, Cohen L, Leonard JH, Granter SR, et al. Array-CGH reveals recurrent genomic changes in Merkel cell carcinoma including amplification of LMyc. J Invest Dermatol 2009; 129: 1547-55; PMID: 19020549; http://dx. doi. org/10. 1038/jid. 2008. 365.
5. Paulson KG, Iyer JG, Tegeder AR, Thibodeau R, Schelter J, Koba S, Schrama D, Simonson WT, Lemos BD, Byrd DR, et al. Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8C lymphocyte invasion as an independent predictor of survival. J Clin Oncol 2011; 29: 1539-46; PMID: 21422430; http://dx. doi. org/10. 1200/JCO. 2010. 30. 6308.
6. Harms PW, Patel RM, Verhaegen ME, Giordano TJ, Nash KT, Johnson CN, Daignault S, Thomas DG, Gudjonsson JE, Elder JT, et al. Distinct gene expression profiles of viral-and nonviral-associated merkel cell carcinoma revealed by transcriptome analysis. J Invest Dermatol 2013; 133: 936-45; PMID: 23223137; http://dx. doi. org/10. 1038/jid. 2012. 445.
7. Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell 2014; 54: 728-36; PMID: 24905006; http://dx. doi. org/10. 1016/j. molcel. 2014. 05. 016.
8. Evans AG, French CA, Cameron MJ, Fletcher CD, Jackman DM, Lathan CS, Sholl LM. Pathologic characteristics of NUT midline carcinoma arising in the mediastinum. Am J Surg Pathol 2012; 36: 1222-7; PMID: 22790861; http://dx. doi. org/10. 1097/PAS. 0b013e318258f03b.
9. Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 2014; 13: 337-56; PMID: 24751816; http://dx. doi. org/10. 1038/nrd4286.
10. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. Selective inhibition of BET bromodomains. Nature 2010; 468: 1067-73; PMID: 20871596; http://dx. doi. org/10. 1038/nature09504.
11. Asangani IA, Dommeti VL, Wang X, Malik R, CieslikM, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 2014; 510: 278-82; PMID: 24759320; http://dx. doi. org/10. 1038/nature13229.
12. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-17; PMID: 21889194; http://dx. doi. org/10. 1016/j. cell. 2011. 08. 017.
13. Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI, Young RA. Selective inhibition of tumor oncogenes by disruption of superenhancers. Cell 2013; 153: 320-34; PMID: Can't; http://dx. doi. org/10. 1016/j. cell. 2013. 03. 036.
14. Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, Hoke HA, Young RA. Super-enhancers in the control of cell identity and disease. Cell 2013; 155: 934-47; PMID: 24119843; http://dx. doi. org/10. 1016/j. cell. 2013. 09. 053.
15. Zhang W, Prakash C, Sum C, Gong Y, Li Y, Kwok JJ, Thiessen N, Pettersson S, Jones SJ, Knapp S, et al. Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4C T cells. J Biol Chem 2012; 287: 43137-55; PMID: 23086925; http://dx. doi. org/10. 1074/jbc. M112. 413047.
16. Zippo A, Serafini R, Rocchigiani M, Pennacchini S, Krepelova A, Oliviero S. Histone crosstalk between H3S10ph and H4K16ac generates a histone code that mediates transcription elongation. Cell 2009; 138: 1122-36; PMID: 19766566; http://dx. doi. org/10. 1016/j. cell. 2009. 07. 031.
17. Hargreaves DC, Horng T, Medzhitov R. Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 2009; 138: 129-45; PMID: 19596240; http://dx. doi. org/10. 1016/j. cell. 2009. 05. 047.
18. Shao Q, Kannan A, Lin Z, Stack BC, Suen JY, Gao L. BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo. Cancer Res 2014; 74: 7090-102; PMID: 25277525; http://dx. doi. org/10. 1158/0008-5472. CAN-14-0305.
19. Kwun HJ, Shuda M, Feng H, Camacho CJ, Moore PS, Chang Y. Merkel cell polyomavirus small T antigen controls viral replication and oncoprotein expression by targeting the cellular ubiquitin ligase SCFFbw7. Cell Host Microbe 2013; 14: 125-35; PMID: 23954152; http://dx. doi. org/10. 1016/j. chom. 2013. 06. 008.
20. Lin Z, McDermott A, Shao L, Kannan A, Morgan M, Stack BC, Moreno M, Davis DA, Cornelius LA, Gao L. Chronic mTOR activation promotes cell survival in Merkel cell carcinoma. Cancer Lett 2014; 344: 272-81; PMID: 24262658; http://dx. doi. org/10. 1016/j. canlet. 2013. 11. 005.
21. Hafner C, Houben R, Baeurle A, Ritter C, Schrama D, Landthaler M, Becker JC. Activation of the PI3K/AKT pathway in Merkel cell carcinoma. PLoS One 2012; 7: e31255; PMID: 22363598; http://dx. doi. org/10. 1371/journal. pone. 0031255.
22. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler D. The human genome browser at UCSC. Genome Res 2002; 12: 996-1006; PMID: 12045153; http://dx. doi. org/10. 1101/gr. 229102.
23. Di Micco R, Fontanals-Cirera B, Low V, Ntziachristos P, Yuen SK, Lovell CD, Dolgalev I, Yonekubo Y, Zhang G, Rusinova E, et al. Control of embryonic stem cell identity by BRD4-dependent transcriptional elongation of super-enhancer-associated pluripotency genes. Cell Rep 2014; 9: 234-47; PMID: 25263550; http://dx. doi. org/10. 1016/j. celrep. 2014. 08. 055.
24. Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, Etchin J, Lawton L, Sallan SE, Silverman LB, et al. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 2014; 346: 1373-7; PMID: 25394790; http://dx. doi. org/10. 1126/science. 1259037.
25. Yashiro-Ohtani Y, Wang H, Zang C, Arnett KL, Bailis W, Ho Y, Knoechel B, Lanauze C, Louis L, Forsyth KS, et al. Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia. Proc Natl Acad Sci U S A 2014; 111: E4946-53; PMID: 25369933; http://dx. doi. org/10. 1073/pnas. 1407079111.
26. Ren B. Transcription: enhancers make non-coding RNA. Nature 2010; 465: 173-4; PMID: 20463730; http://dx. doi. org/10. 1038/465173a.
27. Lam MT, Li W, Rosenfeld MG, Glass CK. Enhancer RNAs and regulated transcriptional programs. Trends Biochem Sci 2014; 39: 170-82; PMID: 24674738; http://dx. doi. org/10. 1016/j. tibs. 2014. 02. 007.
28. Lai F, Shiekhattar R. Enhancer RNAs: the new molecules of transcription. Curr Opin Genet Dev 2014; 25: 38-42; PMID: 24480293; http://dx. doi. org/10. 1016/j. gde. 2013. 11. 017.